Neurocrine Biosciences Inc. — Sponsor Intelligence | 18 EU Trials

Filter these 18 trials by condition, phase, country and more.

Open in Search →

18 Registered trials

11 Recruiting

6 Completed trials

21 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 12 Phase II: 2 Phase I: 2 Phase I (Other): 2

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Schizophrenia 4 Athetosis 1 Dyskinesia 1 Choreoathetosis 1 Chorea 1 Rheumatoid arthritis 1 Cerebral palsy 1 Dystonia 1

Top IMPs

9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE 5 CRINECERFONT 3 VALBENAZINE DITOSYLATE 3 DIRECLIDINE 2 NBI-1117570 1

All trials

18 total

A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy o… Pending

2025-525113-22-00 Phase I 2 countries
Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting

2025-521216-19-00 Phase III 3 countries DIRECLIDINE
Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Phase III 16 countries 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE …
Effect of NBI-921355 on corticospinal excitability in healthy participants Recruiting

2025-524134-26-00 Phase I (Other) 1 country
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Recruiting

2025-521868-35-00 Phase II 3 countries NBI-1117570
Evaluation of NBI-1117568 in Inpatient Adults with Schizophrenia Recruiting

2025-521215-39-00 Phase III 3 countries DIRECLIDINE
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 Phase III 4 countries 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE …
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 Phase III 5 countries 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE …
Pharmacokinetics, safety, and tolerability of crinecerfont in subjects with congenital adrenal hyperplasia who are less than 2 years old Recruiting

2024-514127-42-00 Phase II 1 country CRINECERFONT
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 Phase III 3 countries 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE …
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519421-37-00 Phase III 4 countries 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE …
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults. Recruiting

2023-508305-24-00 Phase I 1 country
Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia Ended

2023-509170-33-00 Phase III 7 countries CRINECERFONT
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended

2023-509171-16-00 Phase III 12 countries CRINECERFONT
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults Ended

2023-508814-40-00 Phase I (Other) 1 country
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Ended

2022-502713-29-00 Phase III 5 countries VALBENAZINE DITOSYLATE
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Phase III 6 countries VALBENAZINE DITOSYLATE
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Phase III 6 countries VALBENAZINE DITOSYLATE

Showing 1–18 of 18 trials

← All sponsors A–Z